GlassScriptPhysician profile
Oumar Sano
NPI 1770912123
$4,001.56
in general payments reported to CMS, 2019-2025
24 companies · $656 in 2025
The $656 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.39 · 2022: $1,031 · 2023: $1,002 · 2024: $1,264 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $439.23 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $420.01 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $413.29 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $406.49 | 2022-2025 | Lybalvi, Vivitrol |
| Novo Nordisk INC | $284.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $277.67 | 2022-2025 | Minimed 780g, Minimed 770g |
| Neurocrine Biosciences, INC. | $220.09 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.21 | 2023-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $192.62 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $150.64 | 2021-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $135.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $124.00 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.20 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Braeburn INC. | $106.75 | 2023 | Brixadi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $100.84 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $68.29 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.73 | 2022 | |
| Pfizer INC. | $49.86 | 2022-2023 | |
| Indivior INC. | $23.53 | 2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $23.39 | 2021 | |
| Glaxosmithkline, LLC. | $18.49 | 2025 | Pediarix, Rotarix, Bexsero |
| Merck Sharp & Dohme LLC | $16.45 | 2024 | Gardasil 9, Gardasil |
| Sanofi Pasteur INC. | $13.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oumar Sano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.